Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 13, 2022

Deep Lens announces partnership for clinical trial programme expansion

Deep Lens’ VIPER can detect qualified patients for clinical trials by pre-screening all patients from HOA CNY’s EMR.

Deep Lens has announced a partnership with Hematology-Oncology Associates of Central New York (HOA CNY) for the expansion of a clinical trial programme.

The alliance will also work on enhancing the trial matching expertise of the US-based comprehensive cancer centre.

Through the collaboration, the clinical research programme of HOA CNY will be broadened by increasing the breadth of trials offered to patients. This will aid in expediting the trial matching process, permitting patients to enter the trials quickly.

According to estimates, more than 15,000 oncology clinical trials are actively enrolling participants with less than one in 30 patients being part of a trial. 

Due to reduced trial site resources, finding eligible participants is time-consuming, particularly with the increase in the complexity of trial protocols. 

The technology and other services of Deep Lens assist care teams by automating the detection of possibly eligible individuals during the time of diagnosis and matching them to appropriate trials on a real-time basis.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Deep Lens’ integrated Cloud platform VIPER can automatically detect qualified individuals for trials by pre-screening all patients from EMR (OncoEMR) of HOA CNY and integrating pathology feeds and molecular data feeds from Guardant Health, Foundation Medicine Caris Life Sciences.

Deep Lens provider sales vice-president Tyrone Richardson said: “HOA CNY is an exceptional community-based oncology practice that already has deep relationships with leading institutions and organisations that provide them with the ability to conduct and participate in clinical research. 

“Deep Lens’ technology will add to the already-robust HOA CNY research programme by bringing more trials to the practice and improving efficiencies related to the matching and enrolment process.”

Last December, Deep Lens announced the launch of its Real-Time Feasibility tool that can detect eligible patients and choose the efficient trial centres in the Deep Lens Unity Network for cancer clinical trials in real-time.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU